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Introduction {#jcsm12469-sec-0005}
============

Studies of body composition assessed by analyses of computed tomography (CT) images suggest that muscle depletion is a negative prognostic factor for survival in advanced cancer including non‐small cell lung cancer (NSCLC)[1](#jcsm12469-bib-0001){ref-type="ref"}, [2](#jcsm12469-bib-0002){ref-type="ref"}, [3](#jcsm12469-bib-0003){ref-type="ref"}, [4](#jcsm12469-bib-0004){ref-type="ref"} and is associated with severe toxicity from systemic cancer therapy.[5](#jcsm12469-bib-0005){ref-type="ref"}, [6](#jcsm12469-bib-0006){ref-type="ref"}, [7](#jcsm12469-bib-0007){ref-type="ref"}, [8](#jcsm12469-bib-0008){ref-type="ref"}, [9](#jcsm12469-bib-0009){ref-type="ref"} Similar associations have been observed for patients with low skeletal muscle density (SMD),[3](#jcsm12469-bib-0003){ref-type="ref"}, [10](#jcsm12469-bib-0010){ref-type="ref"}, [11](#jcsm12469-bib-0011){ref-type="ref"}, [12](#jcsm12469-bib-0012){ref-type="ref"}, [13](#jcsm12469-bib-0013){ref-type="ref"}, [14](#jcsm12469-bib-0014){ref-type="ref"} which is believed to reflect fat infiltration and reduced muscle quality.[15](#jcsm12469-bib-0015){ref-type="ref"} It appears that both muscle depletion and low muscle density are secondary to malignant diseases and are linked to cancer cachexia, although the exact pathophysiology is not completely understood.[16](#jcsm12469-bib-0016){ref-type="ref"}

Other conditions, such as heart, vascular, lung and muscle diseases, and diabetes, are also associated with muscle wasting.[17](#jcsm12469-bib-0017){ref-type="ref"}, [18](#jcsm12469-bib-0018){ref-type="ref"}, [19](#jcsm12469-bib-0019){ref-type="ref"}, [20](#jcsm12469-bib-0020){ref-type="ref"}, [21](#jcsm12469-bib-0021){ref-type="ref"}, [22](#jcsm12469-bib-0022){ref-type="ref"}, [23](#jcsm12469-bib-0023){ref-type="ref"} Many cancer patients have severe co‐morbidity, and several studies have shown that co‐morbidity is an independent negative prognostic factor.[24](#jcsm12469-bib-0024){ref-type="ref"}, [25](#jcsm12469-bib-0025){ref-type="ref"}, [26](#jcsm12469-bib-0026){ref-type="ref"}, [27](#jcsm12469-bib-0027){ref-type="ref"}, [28](#jcsm12469-bib-0028){ref-type="ref"}, [29](#jcsm12469-bib-0029){ref-type="ref"} Studies of patients with colorectal cancer have demonstrated that patients with co‐morbidity had lower skeletal muscle mass than other patients,[30](#jcsm12469-bib-0030){ref-type="ref"}, [31](#jcsm12469-bib-0031){ref-type="ref"} possibly indicating that co‐morbidity should be adjusted for in studies of the clinical importance of muscle measures in cancer patients.

Lung cancer patients have a relatively high median age at the time of diagnosis (approximately 71 years)[32](#jcsm12469-bib-0032){ref-type="ref"} and appears to have more co‐morbidity than other cancer patients, probably due to older age and because most lung cancer patients have a history of tobacco smoking.[26](#jcsm12469-bib-0026){ref-type="ref"}, [27](#jcsm12469-bib-0027){ref-type="ref"}, [33](#jcsm12469-bib-0033){ref-type="ref"}

We have previously investigated the associations between co‐morbidity and treatment outcomes in patients participating in a randomized Phase III trial of first‐line chemotherapy in advanced NSCLC[34](#jcsm12469-bib-0034){ref-type="ref"} and found that patients with severe co‐morbidity had similar survival as other patients but experienced more severe toxicity.[35](#jcsm12469-bib-0035){ref-type="ref"} This cohort was also included in our previous studies of the prognostic and predictive role of muscle measures in advanced NSCLC, in which we found that low SMD was a negative prognostic factor and that patients with a low SMI experienced more haematologic toxicity.[13](#jcsm12469-bib-0013){ref-type="ref"}, [36](#jcsm12469-bib-0036){ref-type="ref"} In the present study, we have combined the data from these studies and aim to investigate whether there were any associations between severe co‐morbidity and skeletal muscle measures among advanced NSCLC patients.

Materials and methods {#jcsm12469-sec-0006}
=====================

Approvals {#jcsm12469-sec-0007}
---------

The study was approved by the Regional Committee for Medical and Health Research Ethics in South‐East of Norway and was conducted according to the Declaration of Helsinki and its later amendments.

Patients {#jcsm12469-sec-0008}
--------

Patients enrolled in a randomized Phase III study comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as a first‐line therapy in advanced NSCLC were analysed.[34](#jcsm12469-bib-0034){ref-type="ref"} The main end points were patient reported health‐related quality of life, overall survival, and toxicity. Eligible patients gave written informed consent, had Stage IIIB or stage IV NSCLC, World Health Organization performance status 0--2, and adequate bone marrow, kidney, and liver function for chemotherapy. All other co‐morbidities were allowed. Patients who were ≥75 years had a 25% dose reduction from the first course.

Assessment of co‐morbidity {#jcsm12469-sec-0009}
--------------------------

Co‐morbidity was measured at baseline using the Cumulative Illness Rating Scale for Geriatrics (CIRS‐G). This index contains 14 scales that each represents different organ systems. The severity of disorders on each scale is graded from 0 to 4. '0\' indicates no problem, '1\' a current mild problem or past significant problem, '2\' a moderate disability or morbidity requiring 'first line\' therapy, '3\' a severe/constant significant disability or an 'uncontrollable\' chronic problem, and '4\' an extremely severe/immediate treatment required/end organ failure/severe impairment in function.

Two researchers, both oncologists, independently assessed co‐morbidity for each patient from the hospital medical records according to the CIRS‐G manual.[37](#jcsm12469-bib-0037){ref-type="ref"} Any differences in scores were discussed, and the two physicians agreed on a final score. The total score (i.e. sum of the scores on all scales) and the numbers of grades 3 and 4 scores were calculated for each patient.

Classification of co‐morbidity {#jcsm12469-sec-0010}
------------------------------

There are no established cut‐off values for the definition of 'severe\' co‐morbidity when using the CIRS‐G. In the present study, the prevalence of grade 4 conditions was low (9%), and when scoring co‐morbidity, we found it difficult to accurately distinguish between grade 3 and grade 4 severity. As in our previous study of co‐morbidity, we therefore defined 'severe co‐morbidity\' as the presence of ≥1 CIRS‐G score 3 or 4.[35](#jcsm12469-bib-0035){ref-type="ref"}

Body mass index, muscle measures and appetite loss {#jcsm12469-sec-0011}
--------------------------------------------------

Body mass index (BMI) (weight/height^2^) was categorized as underweight (\<20.0 for patients \<70 years and \<22 for patients ≥70 years), normal (20.0/22.0--24.9), overweight (25.0--29.9), and obese (≥30.0).[38](#jcsm12469-bib-0038){ref-type="ref"} The muscle measures were assessed from CT scans of the thorax and upper abdomen taken within 4 weeks before chemotherapy commenced. The CT scans were analysed using the SliceOMatic software (v.4.3 Tomovision, Montreal Canada) by three observers blinded for patient data. The total cross‐sectional area of skeletal muscle (cm^2^) was quantified from images at the L3 level, which is strongly correlated to the whole body skeletal muscle mass. Well‐established thresholds of Hounsfield units (HU) in the range of --29 to +150 HU were used for demarcation of muscle tissue.[15](#jcsm12469-bib-0015){ref-type="ref"} The total cross‐sectional skeletal muscle area (cm^2^) was divided by height (m^2^) and expressed as skeletal muscle index (SMI) (cm^2^/m^2^). SMD, expressed in HU, was reported for the entire muscle area at the L3 level.

Appetite loss was reported by the patients on the baseline quality of life questionnaire (the EORTC QLQ‐C30).[39](#jcsm12469-bib-0039){ref-type="ref"} Patients reporting 'not at all\' were defined as having no appetite loss, while patients reporting 'a little\', 'quite a bit\', and 'very much\' were defined as having appetite loss.

Statistical considerations {#jcsm12469-sec-0012}
--------------------------

Skeletal muscle index and SMD were first compared between patients with and patients without severe co‐morbidity using the Student\'s *t*‐test. Because not all co‐morbidities registered by the CIRS‐G are known to cause muscle depletion, we performed subgroup analyses to investigate whether patients with the three most commonly observed severe co‐morbidities known to be associated with muscle depletion (i.e. respiratory,[22](#jcsm12469-bib-0022){ref-type="ref"} heart,[18](#jcsm12469-bib-0018){ref-type="ref"} and vascular disease[17](#jcsm12469-bib-0017){ref-type="ref"}, [20](#jcsm12469-bib-0020){ref-type="ref"}) had lower SMI or SMD than the remaining patients in our cohort. To assess the independent impact of overall severe co‐morbidity on SMI and SMD, simple and multiple linear regression analyses controlling for baseline patient characteristics and stage of disease were performed. The significance level was defined as *P* \< 0.05. The statistical analyses were performed using the SPSS v25 software.

Results {#jcsm12469-sec-0013}
=======

Patients {#jcsm12469-sec-0014}
--------

From May 2005 until June 2006, 436 patients were enrolled in the Phase III trial. Co‐morbidity data were missing in 23 patients, and CT slides were missing or not analysable in 160. Thus, 263 patients (60%) were analysed in the present study (*Figure* [1](#jcsm12469-fig-0001){ref-type="fig"}).

![Patient selection. CT, computed tomography.](JCSM-10-1347-g001){#jcsm12469-fig-0001}

Baseline characteristics for all patients are shown in *Table* [1](#jcsm12469-tbl-0001){ref-type="table"}. Median age was 66 years, 20.9% were ≥ 75 years, 57.0% were men, 78.7% had performance status 0--1, 25.9% had Stage IIIB, 50.2% received pemetrexed/carboplatin, 11.4% reported appetite loss at baseline, 92.4% were former or current smokers, and the mean BMI was 24 (range: 14--36). According to BMI, 22.8% were underweight and 6.8% were obese. The baseline characteristics were comparable between patients included and patients excluded in the present study (data not shown).

###### 

Baseline patient characteristics

                                      All patients (*n* = 263)                                                       Severe co‐morbidity (*n* = 127)   No severe co‐morbidity (*n* = 136)                                 
  ----------------------------------- ------------------------------------------------------------------------------ --------------------------------- ------------------------------------ --------------- ------ ------ ------
  Age, years                          Mean (range)                                                                   65.5 (37--90)                     67.7 (48--85)                        63.4 (37--90)                 
  ≥70 years                           96                                                                             36.5                              55                                   43.3            41     30.1   
  Gender                              Male                                                                           150                               57.0                                 79              62.2   71     52.2
  Female                              113                                                                            43.0                              48                                   37.8            65     47.8   
  Stage of disease                    IIIB                                                                           68                                25.9                                 40              31.5   28     20.6
  IV                                  195                                                                            74.1                              87                                   68.5            108    79.4   
  Performance status                  0--1                                                                           208                               78.7                                 99              78.0   109    19.9
  2                                   55                                                                             21.3                              28                                   22.0            27     80.1   
  Treatment                           Pemetrexed/carboplatin                                                         132                               50.2                                 57              44.9   75     55.1
  Gemcitabin/carboplatin              131                                                                            49.8                              70                                   55.1            61     44.9   
  Appetite loss                       Yes                                                                            30                                11.4                                 14              11.0   16     11.8
  No                                  229                                                                            87.1                              112                                  88.2            117    86.0   
  Unknown                             4                                                                              1.5                               1                                    0.8             3      2.2    
  Body mass index                     Underweight (\<20.0 for patients \<70 years and \<22 for patients ≥70 years)   60                                22.8                                 29              22.8   31     22.8
  Normal weight (20.0/22.0 to 24.9)   115                                                                            43.7                              53                                   41.7            62     45.6   
  Overweight (25.0 to 29.9)           70                                                                             26.6                              35                                   27.6            35     25.7   
  Obesity (≥30)                       18                                                                             6.8                               10                                   7.9             8      5.9    
  Smoking history                     Never smoker                                                                   17                                6.5                                  6               4.7    11     8.1
  Former or current smoker            243                                                                            92.4                              120                                  94.4            123    90.4   
  Unknown                             3                                                                              1.1                               1                                    0.8             2      1.4    

Co‐morbidity {#jcsm12469-sec-0015}
------------

The distribution of the total CIRS‐scores is shown in *Figure* [2](#jcsm12469-fig-0002){ref-type="fig"}. The median total CIRS‐G score was 7 (range 0--16), 2% had no co‐morbidity, 5% had no CIRS‐G scores \> grade 1, 48% had severe co‐morbidity (one or more grades 3 and 4 CIRS‐G scores), and 11% had two or more grades 3 and 4 CIRS‐G scores. Most grades 3 and 4 CIRS‐G scores were registered on the respiratory (26%), heart (10%), and vascular (7%) scales (*Figure* [2](#jcsm12469-fig-0002){ref-type="fig"}).

![Co‐morbidity scores. (A) Distribution of the total CIRS‐G scores (sum of the scores on all 14 organ scales). (B) Distribution of severe co‐morbidity (grades 3 and 4 CIRS‐G scores). CIRS‐G, Cumulative Illness Rating Scale for Geriatrics.](JCSM-10-1347-g002){#jcsm12469-fig-0002}

Muscle measures {#jcsm12469-sec-0016}
---------------

Overall, the mean SMI was 44.7 cm^2^/m^2^ (range: 26.9--70.7) and was higher in men than in women (48.6 vs. 39.6 cm^2^/m^2^; *P* \< 0.001). The mean SMD was 37.3 HU (range: 15.6--60.4) and was similar for men and women (37.1 vs. 37.6 HU; 0.58).

When comparing patients with and without severe co‐morbidity, there were no significant differences in the median SMI in the overall population (44.5 vs. 45.0 cm^2^/m^2^; 0.66), in men (48.5 vs. 48.7 cm^2^/m^2^; 0.85) or women (39.1 vs. 39.9 cm^2^/m^2^; 0.47), and there were no significant differences in SMI between those with and those without severe heart disease (47.5 vs. 44.4 cm^2^/m^2^; 0.065), those with and without severe respiratory disease (44.4 vs. 44.8 cm^2^/m^2^; 0.68), or those with and without severe vascular disease (46.0 vs. 44.6 cm^2^/m^2^; 0.50)---neither in the overall population or among men or women (*Table* [2](#jcsm12469-tbl-0002){ref-type="table"}).

###### 

Muscle measures in subgroups defined by overall and the most common severe co‐morbidities

                                          L3 SMI                                      *P*           SMD       *P*          
  --------------------------------------- ------------------------------------------- ------------- --------- ------------ -------
  Overall study population                All patients (*n* = 263)                    44.7 ± 8.1    \<0.001   37.3 ± 8.3   0.582
  Men (*n* = 150)                         48.6 ± 7.5                                  37.3 ± 8.3                           
  Women (*n* = 113)                       39.6 ± 5.7                                  37.6 ± 9.1                           
  All patients                            No severe co‐morbidity (*n* = 136)          44.5 ± 7.7    0.663     38.9 ± 8.5   0.001
  Severe co‐morbidity (*n* = 127)         45.0 ± 8.5                                  35.6 ± 7.9                           
  Men                                     No severe co‐morbidity (*n* = 71)           48.7 ± 6.9    0.850     38.7 ± 8.1   0.013
  Severe co‐morbidity (*n* = 79)          48.5 ± 8.0                                  35.6 ± 7.2                           
  Women                                   No severe co‐morbidity (*n* = 65)           39.9 ± 5.9    0.467     39.1 ± 8.9   0.045
  Severe co‐morbidity (*n* = 48)          39.1 ± 5.5                                  35.6 ± 9.1                           
  All patients                            No severe heart disease (*n* = 236)         44.4 ± 8.0    0.065     37.9 ± 8.3   0.002
  Severe heart disease (*n* = 27)         47.5 ± 8.5                                  32.5 ± 7.8                           
  Men                                     No severe heart disease (*n* = 128)         48.5 ± 7.4    0.748     37.8 ± 7.6   0.009
  Severe heart disease (*n* = 22)         49.1 ± 8.4                                  32.8 ± 7.7                           
  Women                                   No severe heart disease (*n* = 108)         39.5 ± 5.7    0.777     37.9 ± 9.1   0.111
  Severe heart disease (*n* = 5)          40.3 ± 5.1                                  31.3 ± 9.1                           
  All patients                            No severe respiratory disease (*n* = 196)   44.8 ± 8.0    0.677     37.7 ± 8.3   0.166
  Severe respiratory disease (*n* = 67)   44.4 ± 8.6                                  36.1 ± 8.5                           
  Men                                     No severe respiratory disease (*n* = 110)   48.8 ± 7.3    0.605     37.7 ± 7.9   0.119
  Severe respiratory disease (*n* = 40)   48.1 ± 8.2                                  35.4 ± 7.3                           
  Women                                   No severe respiratory disease (*n* = 86)    39.8 ± 5.7    0.464     37.8 ± 8.9   0.692
  Severe respiratory disease (*n* = 27)   38.9 ± 5.8                                  37.0 ± 10.1                          
  All patients                            No severe vascular disease (*n* = 244)      44.6 ± 8.1    0.500     37.4 ± 8.5   0.372
  Severe vascular disease (*n* = 18)      46.0 ± 9.4                                  35.6 ± 7.3                           
  Men                                     No severe vascular disease (*n* = 135)      48.6 ± 7.5    0.814     37.1 ± 7.9   0.606
  Severe vascular disease (*n* = 14)      49.1 ± 8.0                                  37.1 ± 7.9                           
  Women                                   No severe vascular disease (*n* = 109)      39.7 ± 5.7    0.109     37.8 ± 9.1   0.439
  Severe vascular disease (*n* = 4)       35.1 ± 4.5                                  34.1 ± 10.9                          

The patients with severe co‐morbidity did, however, have a significantly lower median SMD (35.6 vs. 38.9 HU; 0.001) both in the overall population, among men (35.6 vs. 38.7 HU; 0.013) and among women (35.6 vs. 29.1 HU; 0.045). Subgroup analyses revealed that the main reason was a significant difference in SMD between patients with and patients without severe heart disease (32.5 vs. 37.9 HU; 0.002). There were no significant differences in SMD between those with and those without severe respiratory disease (36.1 vs. 37.7 HU; 0.17), or those with and without severe vascular disease (37.4 vs. 35.6 HU; 0.37).

Simple linear regression analyses showed that stage of disease (0.021), gender (*P* \< 0.001), and BMI (*P* \< 0.001) but not severe co‐morbidity (0.663) were significantly associated with SMI and that age (*P* \< 0.001), BMI (*P* \< 0.001), and severe co‐morbidity (0.001) were significantly associated with SMD. Linear multiple regression analyses showed that age (0.028), stage of disease (0.011), gender (*P* \< 0.001), and BMI (*P* \< 0.001) but not severe co‐morbidity (0.68) were significantly associated with SMI, whereas age (*P* \< 0.001), BMI (*P* \< 0.001), and severe co‐morbidity (0.037) were significantly associated with SMD (*Table* [3](#jcsm12469-tbl-0003){ref-type="table"}).

###### 

Linear regression analyses of the associations between baseline patient characteristics and muscle measures

                        SMI     SMD                                                                                                                         
  --------------------- ------- ----------------- --------- ------- ----------------- --------- ------- ---------------- --------- ------- ---------------- ---------
  Severe co‐morbidity   0.44    −1.54 to 2.42     0.663     −0.33   −1.91 to 1.25     0.678     −3.32   −5.31 to −1.32   0.001     −1.91   −3.71 to −0.12   0.037
  Age                   0.001   −0.099 to 0.102   0.977     −0.09   −0.18 to 0.01     0.028     −0.40   −0.49 to −0.31   \<0.001   −0.39   −0.48 to −0.30   \<0.001
  Stage                 −2.63   −4.87 to −0.40    0.021     −2.30   −4.07 to −0.53    0.011     −0.21   −2.53 to 2.12    0.861     −1.10   −3.11 to 0.91    0.282
  Gender                −0.04   −10.71 to −7.38   \<0.001   −8.67   −10.32 to −7.02   \<0.001   0.58    −1.48 to 2.63    0.582     −1.91   −3.78 to −0.04   0.045
  PS                    −0.77   −3.19 to 1.66     0.536     0.23    −1.68 to 2.14     0.813     −0.93   −3.43 to 1.57    0.465     −1.79   −3.96 to 0.37    0.104
  BMI                   0.75    0.53--0.97        \<0.001   0.54    0.34--0.73        \<0.001   −0.57   −0.81 to −0.34   \<0.001   −0.60   −0.82 to −0.38   \<0.001
  Appetite loss         −2.62   −5.73 to 0.50     0.099     −0.53   −3.02 to 1.95     0.672     −1.14   −4.35 to 2.06    0.483     0.90    −1.92 to 3.73    0.530
  Smoking history       0.36    −3.58 to 4.30     0.857     −1.20   −4.46 to 2.07     0.472     2.01    −2.13 to 6.15    0.340     −0.96   −4.67 to 2.75    0.610

CI, confidence interval; SMD, skeletal muscle density.

Discussion {#jcsm12469-sec-0017}
==========

In this study of advanced NSCLC patients, we found that patients with severe co‐morbidity had significantly lower SMD, that is, poorer muscle quality, than other patients, both in the overall population and among men and women, mainly due to a lower SMD among patients with heart disease. There were no significant differences in skeletal muscle index (SMI), that is, muscle mass, between those with severe co‐morbidity and the remaining study population, but there were significant associations between BMI and both SMI and SMD.

To the best of our knowledge, only one former study has reported results related to muscle measures and co‐morbidity in NSCLC patients. Kim *et al*. aimed at investigating whether there were any associations between loss of muscle mass and histologic subtypes of NSCLC. No such association was found in the cohort of 778 patients with varying stages of disease, but in contrast to the present findings, they reported that loss of muscle mass was significantly associated with a high co‐morbidity score. The relationship between SMD and co‐morbidity was not investigated.[40](#jcsm12469-bib-0040){ref-type="ref"} In colorectal cancer, a few more studies have been reported. Two studies investigated co‐morbidity in relation to loss of muscle mass and a decline in muscle density, respectively, and both reported significant associations.[12](#jcsm12469-bib-0012){ref-type="ref"}, [31](#jcsm12469-bib-0031){ref-type="ref"} The results of the most recent and largest study are fully consistent with ours. Xiao *et al*. addressed 3051 patients with non‐metastatic colorectal cancer and found that co‐morbidity was more common among patients with a low SMD compared with those with a normal SMD. There was no difference between patients with a low and those with a normal SMI. Furthermore, subgroup analyses revealed that heart disease was significantly associated with a low SMD, which was also the case in our study. Additionally, they reported significant associations with peripheral vascular disease, diabetes, and renal failure. These results could not be confirmed in our study as renal failure was an exclusion criteria, only one patient had diabetes, and in accordance with the CIRS‐G, 'vascular disease\' did not exclusively include peripheral vascular disease but also conditions such as hypertension and thromboembolism.[37](#jcsm12469-bib-0037){ref-type="ref"}

As demonstrated, present and former findings regarding muscle measures and co‐morbidity in cancer patients are not entirely consistent. One possible explanation is the differences in the choice of co‐morbidity measure. No former study has used the CIRS‐G but rather assessed co‐morbidity by counting ICD codes[31](#jcsm12469-bib-0031){ref-type="ref"} or used the Charlson Comorbidity Index.[12](#jcsm12469-bib-0012){ref-type="ref"}, [30](#jcsm12469-bib-0030){ref-type="ref"}, [40](#jcsm12469-bib-0040){ref-type="ref"} Furthermore, differences in diagnoses and stage of disease may affect the results, as may also possible differences in the distribution of co‐morbidities, smoking habits, and obesity. Overall, however, there are clear indications that muscle wasting in cancer is associated with pre‐existing diseases, and according to our study and the larger study by Xiao *et al*.,[30](#jcsm12469-bib-0030){ref-type="ref"} loss of muscle density might be the most important factor related to subgroups of co‐morbidities. How the latter may be explained is still a question as the pathophysiological mechanisms of muscle wasting in various malignant and non‐malignant diseases are not fully understood. It has been speculated that different findings between muscle abnormalities may be due to a more pronounced decrease in SMD than that of SMI loss under certain chronic disorders.[30](#jcsm12469-bib-0030){ref-type="ref"} In this respect, a major limitation of the present and all former studies is the lack of longitudinal, repeated muscle measurements. Thus, whether muscle wasting, and in particular loss of density, has already occurred in patients with pre‐existing co‐morbidities, or if the cancer disease interacts to initiate or accelerate the process, cannot yet be decided. To answer these questions, further research is needed.

The differences in SMD between patients with and patients without severe co‐morbidity and between patients with and patients without severe heart disease were statistically significant. The clinical relevance of the observed differences of 3.3--5.4 HU is, however, not established. But in a former study on a larger sample of advanced NSCLC patients, which included the present cohort, we found a significant association between SMD and survival, and a Cox regression analysis showed that an incremental increase in SMD of 1 HU was associated with a 2% decrease in the risk of death,[13](#jcsm12469-bib-0013){ref-type="ref"} corresponding to a risk reduction of death of 6.5--10.4% for the aforementioned differences in SMD observed in the present study. Further studies are, however, required to establish the clinical relevance of differences in SMD not only for survival but also for physical function. Including tests of physical performance such as handgrip strength in studies of cancer patients receiving chemotherapy is feasible[41](#jcsm12469-bib-0041){ref-type="ref"} and might improve our understanding of the implications of differences in SMD and help define thresholds for abnormal SMD that are generally applicable. Studies show that the SMD distribution and also thresholds for survival differences differ between patient cohorts, age groups, and regions.[1](#jcsm12469-bib-0001){ref-type="ref"}, [3](#jcsm12469-bib-0003){ref-type="ref"}, [13](#jcsm12469-bib-0013){ref-type="ref"}, [42](#jcsm12469-bib-0042){ref-type="ref"} One factor that may contribute is the variation in the BMI distribution. As observed in our and other studies, there are significant associations between BMI and both SMI and SMD.[43](#jcsm12469-bib-0043){ref-type="ref"} Thus, studies of large cohorts of both healthy individuals and patients with different ethnicities, age, and BMI using standardized CT protocols and preferably physical functional tests are probably needed in order to establish more generally applicable thresholds for abnormal SMD.

A limitation of our study is the lack of information about protocols for the CT scans. It has been shown that the thickness of CT slides, use of contrast media, and tube voltage might influence the SMI and SMD values.[43](#jcsm12469-bib-0043){ref-type="ref"}, [44](#jcsm12469-bib-0044){ref-type="ref"} The body composition analyses were not pre‐planned, and the study protocol did not comprise recommendations for how the CT scans should be performed in order to optimize assessment of the muscle measures, although most of the patients did receive contrast injections according to Norwegian recommendations for diagnostic CT scans. Nevertheless, there might be variations in all three variables that might have influenced our measurements of SMI and SMD. Whether this explains the somewhat different results between our study and some of the other studies of co‐morbidity and muscle measures is not possible to assess because details about CT protocols are seldom provided.[12](#jcsm12469-bib-0012){ref-type="ref"}, [30](#jcsm12469-bib-0030){ref-type="ref"}, [40](#jcsm12469-bib-0040){ref-type="ref"}

The strengths of the present study are the use of otherwise well‐established methods for the analyses of the CT slides[3](#jcsm12469-bib-0003){ref-type="ref"} and the widely accepted attenuation ranges for demarcation of the muscle area on the CT slides.[15](#jcsm12469-bib-0015){ref-type="ref"} The patients\' characteristics including the distributions of co‐morbidity, SMI and SMD, and overall survival in our study cohort are similar to other studies of advanced NSCLC, except that fewer patients were obese.[3](#jcsm12469-bib-0003){ref-type="ref"}, [13](#jcsm12469-bib-0013){ref-type="ref"}, [24](#jcsm12469-bib-0024){ref-type="ref"}, [28](#jcsm12469-bib-0028){ref-type="ref"}, [29](#jcsm12469-bib-0029){ref-type="ref"}, [33](#jcsm12469-bib-0033){ref-type="ref"}, [45](#jcsm12469-bib-0045){ref-type="ref"}, [46](#jcsm12469-bib-0046){ref-type="ref"} Thus, we consider our cohort representative for advanced NSCLC patients receiving palliative chemotherapy. For co‐morbidity assessment, we used the CIRS‐G, which has a good inter‐rater and test--retest reliability, has been used in several cancer studies,[25](#jcsm12469-bib-0025){ref-type="ref"} and has been found to provide independent prognostic information, also predicting toxicity, in stages I--IV NSCLC.[26](#jcsm12469-bib-0026){ref-type="ref"}, [27](#jcsm12469-bib-0027){ref-type="ref"}, [35](#jcsm12469-bib-0035){ref-type="ref"} In contrast to Charlson Comorbidity Index, however, the CIRS‐G accounts for all coexisting conditions. If, as suggested by Xiao *et al*.,[30](#jcsm12469-bib-0030){ref-type="ref"} some co‐morbid diseases may be more important than others in relation to muscle wasting, significant associations might be obscured by the comprehensiveness of the CIRS‐G.

In conclusion, our data indicate that co‐morbidity is associated with muscle wasting in terms of loss of muscle density in a cohort of cancer patients in which muscle depletion is frequent and often attributed to the malignancy. Thus, co‐morbidity may be a confounder in studies of the clinical impact of SMD in cancer patients. Further studies are, however, needed in order to assess to what extent, for which co‐morbidities this is relevant, and to decide how such co‐morbidities should be adjusted for. Finally, the significant associations between BMI and both SMI and SMD suggest that also BMI might be a confounder in studies of muscle measures in cancer patients.
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